Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) was down 29.3% on Wednesday . The company traded as low as $1.14 and last traded at $1.18. Approximately 2,694,748 shares were traded during mid-day trading, an increase of 885% from the average daily volume of 273,630 shares. The stock had previously closed at $1.67.
A number of equities research analysts have weighed in on RNN shares. HC Wainwright set a $20.00 price target on shares of Rexahn Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 25th. B. Riley set a $8.00 price target on shares of Rexahn Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 13th. Ifs Securities raised shares of Rexahn Pharmaceuticals from an “outperform” rating to a “strong-buy” rating in a research note on Thursday, October 4th. Finally, Zacks Investment Research raised shares of Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research note on Friday, August 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $9.92.
Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last posted its quarterly earnings data on Monday, August 6th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03.
Rexahn Pharmaceuticals Company Profile (NYSEAMERICAN:RNN)
Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.
Featured Story: Discover Your Risk Tolerance
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.